Acute effects of dopaminergic therapy with levodopa/carbidopa on the gastric emptying, blood pressure and superior mesenteric artery blood flow responses to oral glucose in patients with mild to moderate Parkinson’s disease.

Professor Karen Jones, The University of Adelaide0 个研究点目标入组 20 人开始时间: 2024年8月20日最近更新: 2024年8月26日

适应症

试验速览

暂无简介。

•Patients currently taking short-acting levodopa/carbidopa
•Body Mass Index (BMI) 19 - 30 kg/m²
•A diagnosis of idiopathic PD according to the UK brain bank criteria of mild to moderate PD (Hoehn and Yahr Staging <2.5)

•History of diabetes mellitus (or fasting plasma glucose >7.0 mmol/L or HbA1C > or =6.5%), severe respiratory, cardiovascular, haematologic, hepatic and/or renal disease (creatinine clearance <50 mL/min), chronic alcohol abuse or epilepsy or if iron stores, or liver function tests are two times greater than the upper limit of the following normal ranges:
•Alanine aminotransferase (ALT)< 55 U/L
•Alkaline phosphatase (ALP)30 - 110 U/L
•Aspartate transaminase (AST)< 45 U/L
•Total bilirubin2 - 24 µmol/L
•Haemoglobin115 – 165 g/L (Females)
•130 – 180 g/L (Males)
•Ferritin15 – 200 µg/L (Females)
•30 – 300 µg/L (Males)
•Medication that influence BP or GI function
•Patients taking long-acting levodopa preparations
•History of GI disease (unrelated to PD), including known gastroparesis, significant upper GI symptoms and gastric surgery
•Smoking >10 cigarettes/day
•Alcohol consumption > 20 g/day
•Blood donation in the previous 12 weeks
•Pregnancy or breastfeeding
•Inability to withdraw from the morning dose of anti-Parkinsonian medication to allow a washout.
•Contraindications to levodopa/carbidopa, including current treatment with MAO inhibitor, known hypersensitivity, narrow-angle glaucoma, melanoma and suspicious undiagnosed skin lesions.

发起方

Professor Karen Jones, The University of Adelaide